Shots:
- The P-III (BaxHTN) trial assessed baxdrostat (1 or 2mg) vs PBO on top of SoCs in 796 pts with uncontrolled or treatment resistant hypertension over 12wks.; P-III (Bax24) trial readout is expected in late 2025
- Trial met its 1EP, reducing mean seated SBP at 12wks. by 15.7 (2mg) & 14.5 mmHg (1mg), with PBO-adjusted decrease of 9.8 (2mg) & 8.7 (1mg) vs 5.8 mmHg; effects were consistent across subgroups
- Trial also met its 2EPs, showing durable BP reduction with 2mg, greater DBP lowering, & ~3x probability of achieving SBP <130 mmHg; subgroup analysis confirmed 24hr. SBP reduction (-16.9 mmHg) with 2mg & nighttime SBP reduction (-11.7 mmHg) with 1 & 2mg; data presented at ESC’25 & published in The NEJM
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News:- AstraZeneca Reports P-III (PREVAIL) Trial Data of Gefurulimab for Generalised Myasthenia Gravis (gMG)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
